原标题：医治风湿病与生育不对立！
一文读懂！
据调查，不少育龄期的缓慢风湿性疾病（简称"CRD")患者由于忧虑药物或疾病操控不好会损伤孩子，所以对生娃这件大事都抱着消沉复兴惊骇的情绪。
还有研讨显现，不少女人怀孕归于方案之外，而此刻或许正在服用对胎儿有影响的药物，为时已晚，进退维谷。临床上还有不少女人，孕期自行停药不准时复诊，成果孕期或产后病况爆发，影响妊娠结局和哺乳，这都是很风险的状况。
其实，你知道吗？医治CRD和生育并不抵触，鱼与熊掌能够兼得！那么，育龄CRD女人怎么用药？其安全性怎么？会不会损伤孩子？戳下图，给你专业答案：
参考文献
[1] Tincani A et al. Fears and misconceptions of women with chronic rheumatic diseases on their journey to motherhood. EULAR 2018. Abstract FRI0693.
[2] Kavanaugh A et al. Proceedings From the American College of Rheumatology Reproductive Health Summit: The Management of Fertility, Pregnancy, and Lactation in Women With Autoimmune and Systemic Inflammatory Diseases. Arthritis Care Res. 2015;67(3):313–325.
[3] https:///disease/detail/1053/1
[4] van den Brandt S, Zbinden A, Baeten D, Villiger PM, Østensen M and Förger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Research & Therapy. 2017;19:64.
[5] Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016;55(9):1693–1697.
[6] Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68(6):805–11
[7] Keystone E et al, Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis. 2014 Dec;73(12):2094-100. doi: 10.1136/annrheumdis-2013-203695.
[8] Smolen JS et al. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Res Ther. 2015 Sep 10;17:245. doi: 10.1186/s13075-015-0767-2.
[9] Bykerk VP et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: An integrated analysis from clinical trials. Ann Rheum Dis. 2015;74:96–103.
[10] Mahadevan U et al, Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar;11(3):286-92; quiz e24. doi: 10.1016/j.cgh.2012.11.011.
[11] Clowse MEB, Förger F, Hwang C, Thorp J, Dolhain RJEM, van Tubergen A et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE: a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890-1896
[12] Clowse MEB, Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol. 2018 Sep;70(9):1399-1407. doi: 10.1002/art.40508.
[13] Oliver A, Overton C. Diagnosis and management of miscarriage. Practitioner. 2014 May;258(1771):25-8, 3. Review.
责任编辑：
